3Podranski T,Bouillon T,Schumacher PM,et al.Compartmental pharmacoki-netics of dantrolene in adults:do malignant hyperthermia association dosing guidelines work? Anesth Analg,2005,101(6):1695-1699.
4Paul-Pletzer K,Palnitkar SS,Jimenez LS,et al.The skeletal muscle ryanedine receptor identified as a molecular target of[3H]azidudantrolene by photoaffinity labeling.Biochemistry,2001,40 (2):531-542.
5Palnitkar SS,Mickelson JR,louis CF,et al.Pharmacological distinction between dantrolene and ryanodine binding sites:evidence from normal and malignant hyperthermia-suseeptible porcine skeletal muscle.Biochemical Journal,1997,326(pt3):847-852.
6Aleman M,Riehl J,Aldridge BM,et al.Association of a mutation in the ryanodine receptor I gene with equine malignant hyperthermia.Muscle Nerve,2004,30(3):356-365.
7Robinson RL,Curran JL,Ellis FR,et al.Multiple interacting gene pro-ducts may influence susceptibility to malignant hyperthermia.Ann Hum Genet,2000,64(pt4):307-320.
8Sambuughin N,Holley H,Muldoon S,et al.Screening of the entire ryanedine receptor type 1 ceding region for sequence variants associated with ma-lignant hyperthermia susceptibility in the North American population.Anesthesiology,2005,102(3):515-521.
9Chamberlain BK,Volpe P,Fleiscber S,et al.Inhibition of calcium-induced calcium release from purified cardiac sarcoplasmic reticulum vesicles.Journal of Biological Chemistry,1984,259(12):7547-7553.
10Yang TZ,Riehl J,Esteve E,et al.Pharmacologic and functional charac-terization of malignant hyperthermia in the R163C RyR1 knock-in mouse.Anesthesiology,2006,105(6):1164-1175.
